Syntaxin
Syntaxin was a UK-based, Abingdon-headquartered biotech (founded 2005) that engineered bacterial botulinum-toxin protein therapeutics for neurological, inflammatory, and endocrine diseases, raising roughly $71.4M across three equity rounds.
- Company typePrivate
- Founded2005
- HeadquartersAbingdon, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Syntaxin firmographics
Firmographics- Name
- Syntaxin
- Website
- https://syntaxin.com
- Company type
- Private
- Founded year
- 2005
- Headcount range
- 1,001–5,000 employees
- Short description
- Syntaxin was a UK-based, Abingdon-headquartered biotech (founded 2005) that engineered bacterial botulinum-toxin protein therapeutics for neurological, inflammatory, and endocrine diseases, raising roughly $71.4M across three equity rounds.
- Ownership category
- akta.pro rank
Syntaxin industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Syntaxin is headquartered
LocationHeadquarters
- HQ city
- Abingdon
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Syntaxin business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Monthly | One-time purchase of Syntaxin.com domain |
| Subscription | Monthly | Lease to Own payment plan for Syntaxin.com domain |
Distribution channels1 record
Marketing channels1 record
Syntaxin product offering
Product offeringCore offering
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The company operates as a biopharmaceutical research and development firm that leverages proprietary protein engineering approaches, applied to bacterial-derived proteins, to discover and advance novel therapeutic candidates for high-unmet-need disease areas.
Product overview
No active products or services. Syntaxin.com is a premium domain name listed for sale on Atom.com (formerly Squadhelp) at a price of $5,448 (one-time) or $235/month for 24 months. The domain is marketed as suitable for Deep Tech, AI, Coding Assistants, Compilers, DevOps platforms, Biotech research labs, and Pharma startups. No actual company, product portfolio, or service offerings exist under the Syntaxin name as the domain has not been acquired or developed.
Differentiator
Problem solved
Functional benefit
Products and services
- Bacterial-based protein therapeutics
Companies that use Syntaxin
Customer profileSegments2 records
Ideal customer profiles2 records
Syntaxin technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Syntaxin partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Syntaxin competitors and assessment
Company assessmentRegional players
- Abcam: UK-based life-sciences tools and protein-reagent company. Comparable as a UK-headquartered protein-focused biotech, though it operates in research tools rather than therapeutics.
Emerging players
- Revance Therapeutics: Develops next-generation neurotoxin and injectable therapeutics. Comparable as a protein-engineering platform pursuing novel indications and longer-duration toxin variants.
Others
- GenScript ProBio: Protein engineering and biologics CDMO with overlap in recombinant protein development. Relevant ecosystem peer for a bacterial-based protein therapeutics platform.
- Biosortia / ReVance-era UK protein-engineering biotechs (e.g., Syntaxin cohort): Lundbeckfonden Ventures as a co-investor in Syntaxin's Series C means comparable portfolio companies in its neuro-focused biotech portfolio. Useful as benchmarks for European protein-therapeutics development trajectories.
Direct peers
- Evolus: Focused exclusively on next-generation neurotoxins (Jeuveau) — direct adjacent competitor in the engineered botulinum toxin therapeutic market that Syntaxin targets.
Broad incumbents
- Allergan Aesthetics (AbbVie): Owner of BOTOX, the dominant botulinum toxin therapeutic. Directly comparable as a player in engineered bacterial-protein therapeutics for neurological and aesthetic indications.
- Merz Therapeutics: Markets Xeomin (incobotulinumtoxinA), a competing engineered botulinum toxin therapeutic. Direct overlap in Syntaxin's neurological / neuromuscular indication space.
- Ipsen: Global specialty pharma with a leading toxin therapeutics franchise (Dysport). Series C strategic investor in Syntaxin and a natural acquirer / commercial partner for bacterial-protein-based neurological assets.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Syntaxin social profiles
Digital presenceSyntaxin financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syntaxin leadership team
Management profileNumber of profiles
Syntaxin funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syntaxin M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syntaxin
What does Syntaxin do?
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The company operates as a biopharmaceutical research and development firm that leverages proprietary protein engineering approaches, applied to bacterial-derived proteins, to discover and advance novel therapeutic candidates for high-unmet-need disease areas.
When was Syntaxin founded?
Syntaxin was founded in 2005. It employs 1,001 to 5,000 people.
Where is Syntaxin based?
Syntaxin is headquartered in Abingdon, United Kingdom, in the Europe region.
Who are Syntaxin's main competitors?
Abcam is listed as a regional player. Revance Therapeutics is listed as an emerging player. Others are GenScript ProBio and Biosortia / ReVance-era UK protein-engineering biotechs (e.g., Syntaxin cohort). Evolus is listed as a direct peer. Broad incumbents are Allergan Aesthetics (AbbVie), Merz Therapeutics and Ipsen.
Does Syntaxin have an API?
No public API is recorded for Syntaxin.
What industry is Syntaxin in?
Syntaxin's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.